Balancing Benefits and Risks: Examining the Effects of Antenatal Corticosteroids on Preterm Brain Development

**Antenatal corticosteroids (ACS)** have long been recognized as a breakthrough in treating preterm infants, particularly for aiding lung development and improving survival rates. **Research by Nagoya University Graduate School of Medicine** now indicates potential effects of ACS on brain development. Published in the _European Journal of Obstetrics & Gynecology and Reproductive Biology_, the study explores how ACS may affect the bilateral amygdalae and caudate nuclei, crucial for emotional processing and motor control, respectively. The investigation involved 59 preterm infants at Nagoya University Hospital, comparing those exposed to ACS before birth with those who were not. The findings revealed smaller brain volumes in the amygdala and caudate nucleus among ACS-exposed infants, especially for those born at 28 weeks or later. These observations emphasize that while ACS is vital for respiratory health, it might have subtle impacts on brain structure. Dr. Kazuya Fuma highlights the importance of weighing risks and benefits, advocating for optimized ACS administration tailored to gestational age. The study underscores the need for further research to refine the use of ACS and enhance both short- and long-term health outcomes for preterm infants.